

Drug Utilization Review (DUR) Meeting Minutes

March 2, 2016

Members Present: Tanya Schmidt, Laura Schield, Katie Kram, Wendy Brown, Russ Sobotta, Peter Woodrow, Andrea Honeyman, Jeffrey Hostetter, Carlotta McCleary, Michael Booth, Leneika Roehrich

Members Absent: James Carlson, Michael Quast

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

W. Brown called the meeting to order at 1:00 p.m. Chair W. Brown asked for a motion to approve the minutes of the December meeting. M. Booth moved that the minutes be approved, and P. Woodrow seconded the motion. Chair W. Brown called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Second reviews

A motion and second were made at the December meeting to place insulin, steroid inhalers, digestive enzymes, nasal steroids, otic anti-infectives, and ulcer anti-infectives on prior authorization. The topics were brought up for a second review. There was no public comment. The motion to place these medications on prior authorization passed with no audible dissent.

Prior authorization review

A. Murphy gave an update on drugs that have been added to prior authorization. Buphenyl, tetrabenazine, phenoxybenzamine, Miacalcin, Carbaglu, Keveyis, and Strensiq have been added to the >\$3,000 PA. Upravi was added to the PAH PA. Repatha was added to the PCSK9 PA. Crestor, Luzu, Finacea, Kadian (except 200 mg), Nucynta, and Nucynta ER were all removed from PA. A. Murphy also informed the board that there will be generics that require prior authorization when the brand equivalent is preferred and not on prior authorization. Examples include Niaspan, Provigil, Tobradex, and Tindamax.

Glumetza review

B. Joyce reviewed Glumetza with the Board. There was no public comment. T. Schmidt made a motion to place Glumetza on prior authorization. The motion was seconded by J. Hostetter. This topic will be reviewed at the next meeting.

Narcan nasal spray review

B. Joyce reviewed Narcan nasal spray with the Board. A motion was made by L. Schield to place Narcan nasal spray on prior authorization. The motion was seconded by K. Kram. There was no public comment. This topic will be reviewed at the next meeting.

Naltrexone review

B. Joyce reviewed naltrexone with the Board. A motion was made by L. Roehrich to place naltrexone on prior authorization. The motion was seconded by J. Hostetter. There was no public comment. This topic will be reviewed at the next meeting.

Edocrin review

B. Joyce reviewed Edocrin with the Board. A motion was made by T. Schmidt to place Edocrin on prior authorization. K. Kram seconded the motion. There was no public comment. This topic will be reviewed at the next meeting.

Nucala review

B. Joyce reviewed Nucala with the Board. Ted Sheedy, representing GSK, spoke. M. Booth made a motion to place Nucala on prior authorization. P. Woodrow seconded the motion. This topic will be reviewed at the next meeting.

Acitretin review

B. Joyce reviewed acitretin with the Board. There was no public comment. M. Booth made a motion to place acitretin on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Lice medications review

B. Joyce reviewed lice medications with the Board. There was no public comment. J. Hostetter made a motion to place lice medications on prior authorization. M. Booth seconded the motion. This topic will be reviewed at the next meeting.

NK1 receptor antagonists review

B. Joyce reviewed NK1 receptor antagonists with the Board. There was no public comment. T. Schmidt made a motion to place NK1 receptor antagonists on prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Tirosint review

B. Joyce reviewed Tirosint with the Board. There was no public comment. T. Schmidt made a motion to place Tirosint on prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Criteria recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Hostetter moved to approve the new criteria, and M. Booth seconded the motion. Chair W. Brown called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held June 1, 2016 in Bismarck. L. Schield made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. W. Brown adjourned the meeting.

Closed session for profile review

Chair W. Brown called the closed session for profile review to order. Topics discussed included recipient with diabetes receiving medications from different prescribers and risperidone underutilization and the role of MTM. After discussion, a motion was made by L. Schield to adjourn the meeting. L. Roehrich seconded the motion. W. Brown adjourned the meeting.